These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20119843)

  • 1. Tumour necrosis factor inhibitor-related lupus: safety of switching agents.
    Luong JM; Tan BT; Buchanan RR; Schachna L
    Clin Rheumatol; 2010 May; 29(5):551-3. PubMed ID: 20119843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?
    Santiago T; Santiago MG; Rovisco J; Duarte C; Malcata A; da Silva JA
    Clin Rheumatol; 2013 Dec; 32(12):1819-22. PubMed ID: 23955767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.
    Akgül Ö; Kılıç G; Kılıç E; Cüce İ; Özgöçmen S
    Rheumatol Int; 2014 Mar; 34(3):443-4. PubMed ID: 23263496
    [No Abstract]   [Full Text] [Related]  

  • 4. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
    Aghdashi MA; Khadir M; Dinparasti-Saleh R
    Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
    Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.
    Giardina AR; Ferrante A; Ciccia F; Impastato R; Miceli MC; Principato A; Triolo G
    Rheumatol Int; 2010 Sep; 30(11):1437-40. PubMed ID: 19851772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced systemic lupus erythematosus associated with etanercept therapy.
    Shakoor N; Michalska M; Harris CA; Block JA
    Lancet; 2002 Feb; 359(9306):579-80. PubMed ID: 11867114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab.
    Mounach A; Ghazi M; Nouijai A; Ghozlani I; Achemlal L; Bezza A; El Maghraoui A
    Clin Exp Rheumatol; 2008; 26(6):1116-8. PubMed ID: 19210883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
    Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
    Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.
    Mathieu S; Pereira B; Couderc M; Rabois E; Dubost JJ; Soubrier M
    Rheumatology (Oxford); 2013 Jan; 52(1):204-9. PubMed ID: 23065359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept and uveitis: friends or foes?
    Brito-Zerón P; Perez-Alvarez R; Ramos-Casals M;
    Curr Med Res Opin; 2015 Feb; 31(2):251-2. PubMed ID: 25438042
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.
    Thiéfin G; Morelet A; Heurgué A; Diebold MD; Eschard JP
    Joint Bone Spine; 2008 Dec; 75(6):737-9. PubMed ID: 18693125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
    Zou JX; Braun J; Sieper J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S34-7. PubMed ID: 12463444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.